Using post-mortem data, researchers explored similarities and differences between autism, schizophrenia, bipolar disorder, alcoholism, and depression.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
As part of the approval, DermTech will market and sell the pigmented lesions assay in Canada, while samples will be processed at the company's lab in California.
UCSF researchers will use NantHealth's GPS Cancer molecular analysis test in their molecular profiling study of metastatic breast cancer.
Using RNA sequences for thousands of cells, researchers looked at head and neck squamous cell carcinomas and proposed streamlined expression subtypes.
Yale researchers found numerous mRNAs and miRNAs that were differentially expressed in humans, including ones linked to cognition and behavior.
In Nature this week: trove of data from the Genotype Tissue Expression consortium, and more.
Investigators compared RNA sequence data in heart samples from individuals with dilated cardiomyopathy and samples from healthy transplant donor hearts.
Gene expression may offer clues to antibody activity after flu vaccination in individuals under 35, according to expression data for hundreds of individuals.
NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.